Valneva H1 2026: Net Loss Triples to €63.3M on IXCHIQ Charges; Guidance Reaffirmed
VALN is trading near its 52-week low of $4.75 (15% above the low) on light trading volume (0.2× avg).
Summary
Valneva reported a first-half 2026 net loss of €63.3 million, triple the prior-year loss, due to lower sales and IXCHIQ-related charges. Full-year guidance was reaffirmed, and the filing details the April offering and Pharmakon loan terms.
Key Events · Earnings and Guidance · VALN
-
Net Loss Triples to €63.3M
First-half 2026 net loss was €63.3 million, up from €20.8 million in H1 2025, driven by lower product sales and one-time IXCHIQ charges.
-
IXCHIQ Charges Hit Gross Margin
IXCHIQ gross margin was negative, impacted by €9.7 million in external manufacturing cancellation fees and a €4.5 million non-cash inventory impairment.
-
Full-Year Guidance Reaffirmed
Product sales guidance of €135–150 million and total revenues of €145–160 million were reaffirmed despite the H1 loss.
-
April Offering Terms Detailed
The €84 million reserved offering included 15,893,817 shares with warrants at an exercise price of €2.96 per share, potentially raising an additional €47 million.
Analysis · VALN · Life Sciences
Valneva's first-half 2026 results show a net loss of €63.3 million, up from €20.8 million a year earlier, driven by lower product sales and one-time IXCHIQ-related charges including €9.7 million in manufacturing contract cancellation fees and a €4.5 million inventory impairment. The company reaffirmed full-year product sales guidance of €135–150 million and highlighted a solid cash position of €121.5 million, supported by the April reserved offering. The detailed financial statements also reveal the terms of the €84 million offering completed in April, including warrants with an exercise price of €2.96 per share, and the Pharmakon loan carrying $205.2 million at a 9.00% interest rate with no financial covenants. These specifics provide investors with a clearer picture of the company's financial health and capital structure than the earlier news summary.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 29% of the 1483 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VALN was trading at $5.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $537.6M. The 52-week trading range was $4.75 to $12.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.